Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ASCO

<< Previous

Bullboard Posts

Next >>

Post by lonc17on May 25, 2023 5:03pm

316 Views

Post# 35464629

ASCO

First glance.. the six month PFS rate is very eye-catching.

Numbers look good, favouring Pelareorep and providing further support for IND213.

Slight concern about toxicity, which we have not had trouble with before.

I'm expecting the SP to pop up nicely tomorrow morning, but ONC's SP has always responded in unexpected ways.

The data fully support moving to a P3, IMO.

https://meetings.asco.org/abstracts-presentations/220680

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages